« Phisohex Still Available in Canada | Home | Menopause linked to increased risk for gout »
Statins May Significantly Reduce Prostate Tumor Inflammation.
By jeremyc | February 23, 2010
HealthDay (2/22, Preidt) reported that “cholesterol-lowering statins significantly reduce prostate tumor inflammation, which may help lower the risk of disease progression,” according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention. Investigators “examined tissue samples of prostate tumors from 236 men undergoing prostate cancer surgery.” The researchers “concluded that statin use was associated with reduced inflammation within tumors.”
Dietary Supplement May Help Interrupt Growth-Promoting Pathways In Prostate Cancer. MedWire (2/22, Guy) reported, “Australian researchers have developed a dietary supplement which interrupts growth-promoting signaling pathways in prostate cancer cells.” Specifically, there was “a dose-dependent reduction in in vitro LNCaP and PC3 growth of 83 and 93%, respectively, after 72 hours of treatment with 0.64% concentration of supplement.” According to the paper in the Journal of Nutrition, the “supplement is designed for men on active surveillance programs for low-risk prostate cancer and contains ingredients commonly consumed in Mediterranean and East-Asian countries where prostate cancer incidence is lower than in Western societies.”
Skin Patch Containing Minute Doses Of Nitroglycerine May Effectively Treat Prostate Cancer. The UK’s Daily Mail (2/22, Hagan) reported, “A chemical once used as a deadly explosive could be a powerful new treatment for prostate cancer,” UK researchers found after studying 24 patients. Participants wore a “skin patch containing minute doses of nitroglycerine” 24 hours a day for two years, and were also “checked…every few months for their PSA doubling time.” According to the paper in Urology, “within six months, PSA levels had stabilized in all but five of the 24 volunteers. After a year, most were either still stable or even declining.”
Comments are closed.
